Showing 6101-6110 of 7527 results for "".
- Bristol Myers Squibb's Deucravacitinib Performs Well in Phase 2 Study in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/bristol-myers-squibbs-deucravacitinib-performs-well-in-phase-2-study-in-patients-with-psoriatic-arthritis/2460605/Results from an ongoing Phase 2 study evaluating the safety and efficacy of Bristol Myers Squibb's deucravacitinib (BMS-986165) 6mg or 12mg once daily, compared with placebo in
- Arena’s Etrasimod Performs Well in Phase 2b AD Trialhttps://practicaldermatology.com/news/arenas-etrasimod-performs-well-in-phase-2b-ad-trial/2460604/Nearly one-third of participants in the 2 mg etrasimod group achieved clear or almost clear skin, as defined by the validated Investigator Global Assessment (vIGA), the FDA endpoint for Phase 3 registration, according to topline results from Arena’s Phase 2b ADVISE clinical trial evaluating
- Tremfya Reduces Fatigue in PsAhttps://practicaldermatology.com/news/tremfya-reduces-fatigue-in-psa/2460602/The IL-23 blocker Tremfya (guselkumab) improves fatigue in adult patients with active psoriatic arthritis (PsA) and this response is maintained through 52 weeks of active treatment, according to data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2. Tremfya improved
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four
- Ilumya Shows 5-Year Sustained Efficacy and Safety in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-shows-5-year-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis/2460596/Patients with moderate-to-severe plaque psoriasis who continued to receive Ilumya (tildrakizumab-asmn) through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety signals, according to Phase 3 data from the combined reSURFACE 1 and reSURFACE 2
- Two New Studies Suggest Age Is A Primary Determinant Of Melanoma Treatment Resistancehttps://practicaldermatology.com/news/two-new-studies-suggest-age-is-a-primary-determinant-of-melanoma-treatment-resistance/2460595/Age is a primary factor in treatment response in animal and laboratory models of melanoma cells, according to two new studies. The new findings by Johns Hopkins Kimmel Cancer Center and
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi
- Safety and Tolerability Update for LEO's Tralokinumabhttps://practicaldermatology.com/news/safety-and-tolerability-update-for-leos-tralokinumab-1/2460590/LEO Pharma’s tralokinumab is well tolerated when used as monotherapy or in combination therapy with the topical corticosteroid (TCS) mometasone furoate, according to a late-breaking data analysis presented online at European Academy of Dermatology and Ve
- Beiersdorf Inc. Observes 10 Years of dermMentors Residents of Distinctionhttps://practicaldermatology.com/news/beiersdorf-inc-observes-10-years-of-dermmentors-residents-of-distinction/2460577/As part of the dermMentors™ Resident of Distinction Award™, Beiersdorf Inc. sponsored five top dermatology residents to attend the 16th Annual Coastal Dermatology Symposium, held in a Virtual Format for 2020. The 2020 Residents of Distinction are Shaundra Eichsta
- Label Update for Enstilar Foam Highlights Long-Term Use in Adultshttps://practicaldermatology.com/news/label-update-for-enstilar-foam-highlights-long-term-use-in-adults/2460575/The US Prescribing Information (USPI) for Enstilar® (calcipotriene and betamethasone dipropionate) Foam from LEO Pharma A/S now includes data on long-term use in adults with plaque psoriasis. The update results from the FDA approving a supplemental New Drug Application (sNDA).